XVIVO Perfusion AB (publ) has completed a private placement of shares through an accelerated book building procedure, performed by Carnegie Investment Bank, raising approximately SEK 500 million before transaction costs.
XVIVO is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The proceeds from the private placement will be used for: (i) financing of the acquisition of Organ Assist B.V.; (ii) funding the FDA (US Food and Drug Administration) 510k regulatory approval process in the US of Organ Assist’s Kidney Assist Transport device; (iii) funding the regulatory approval processes of the Liver Assist in combination with the STEEN Solution™ technology in the US and other key markets; and (iv) continue to build and strengthen the organization to support the company’s growth strategy and for general corporate purposes.
A number of existing shareholders and new shareholders participated in the private placement, including Bure Equity AB, Swedbank Robur, Eccenovo, The Fourth Swedish National Pension Fund, Lannebo Fonder and Handelsbanken Fonder.
Carnegie Investment Bank acted as Sole Global Coordinator and Bookrunner in connection with the transaction. Baker McKenzie acted as legal advisor to Carnegie Investment Bank. Baker McKenzie’s team consisted of Joakim Falkner, Johanna Flink and Ian Gulam in Stockholm and Megan Schellinger in London.